• 1
    Astoin J, Marivain A, Riveron A, Crucifix M, Lapotre M, Torrens Y. Action de nouveaux alcools alpha-ethyléniques sur le système nerveux central. Eur J Chem Chim Ther 1978;13:417.
  • 2
    Lockard JS, Levy RH. Rhodes PH, Moore DF. Stiripentol in acute/chronic efficacy test in monkey model. Epilepsia 1985;26:70412.
  • 3
    Micheletti G, Vergnes M, Lannes B, et al. Effect of stiripentol on petit mal-like epilepsy in Wistar rat. Epilepsia 1988;29: 709.
  • 4
    Martinez-Lage JM, Loiseau P, Levy RH, et al. Clinical antiepileptic efficacy of stiripentol in resistant partial epilepsies. Epilepsia 1984;25: 673.
  • 5
    Loiseau P, Levy RH, Houin G, Rascol O, Dordain G. Randomized double-blind, parallel, multicenter trial of stiripentol added to CBZ in the treatment of CBZ resistant epilepsies: an interim analysis. Epilepsia 1990;31: 618.
  • 6
    Levy RH, Loiseau P, Guyot M, Blehaut H, Tor J, Moreland TA. Stiripentol kinetics in epilepsy: nonlinearity and interactions. Clin Pharmacol Ther 1984;36:6619.
  • 7
    Mesnil M, Testa B, Jenner P. Ex vivo inhibition of rat brain cy-tochrome P450 activity by stiripentol. Biochem Pharmacol 1988;37:361922.
  • 8
    Renard F, Musial C, Tor JA, Dulac O. Single-blind add-on trial of stiripentol in epileptic children. Epilepsia 1993;34: S74.
  • 9
    Lortie A, Chiron C, Dumas C, Mumford J, Dulac O. Optimizing the indication of vigabatrin in children with refractory epilepsy. J Child Neurol 1997;12:2539.
  • 10
    Coppola G, Plouin P, Chiron C, Robain O, Dulac O. Migrating partial seizures in infancy: a malignant disorder with developmental arrest. Epilepsia 1995;36:101724.
  • 11
    Dravet C, Bureau M, Guerrini R, Giraud N, Roger J. Severe myoclonic epilepsy in infants In: RogerJ, BureauM, DravetC, DreifussFE, PerretA, WolfP. eds. Epileptic syndromes in infancy, children and adolescence 2nd ed. London : John Libbey, 1992; 7588.
  • 12
    Céolin R, Dugué J, Rouland JC, Ralambosoa C, Lepage F. Solid state studies on stiripentol: a novel anticonvulsant drug. Int J Pharm 1991;74:7782.
  • 13
    Loiseau P, Duché B. Stiripentol. In: LevyRH, MattsonRH, Medl-drumBS, eds. Potential antiepileptic drugs. New York : Raven Press 1995: 104556.
  • 14
    Lin HS, Levy RH. Pharmacokinetic profile of a new anticonvulsant, stiripentol in the Rhesus monkey. Epilepsia 1983;24:692702.
  • 15
    Levy RH, Martinez-Lage JM, Tor J, Blehaut H, Gonzalez I, Bain-bridge B. Stiripentol concentration-dose relationship and interaction with CBZ in epileptic patients. Epilepsia 1985;26: 544.
  • 16
    Lockard JS, Levy RH. CBZ plus stiripentol: is polytherapy by design possible? Epilepsia 1988;29:47681.
  • 17
    Loiseau P, Tor J. Stiripentol in absence seizures: an open study. Epilepsia 1987;28: 579.
  • 18
    Loiseau P, Duché B, Tor J. Stiripentol in absence seizures: an open study updated. Epilepsia 1989;30: 639.
  • 19
    Farwell JR, Anderson GD, Kerr BM, Tor JA, Levy RH. Stiripentol in atypical absence seizures in children: an open trial. Epilepsia 1993;34:30511.
  • 20
    Farwell JA, Levy RH, Anderson GD, Tor JA. Stiripentol shows promise in partial complex seizures in children. Epilepsia 1992;33: S81.
  • 21
    Chiron C, Coppola G, Plouin P, Robain O, Renard F. Multifocal epilepsy in infancy: value of stiripentol-clonazepam combination. Epilepsia 1993; 34(suppl.6):73.
  • 22
    Tran A, Vauzelle-Kervroëdan F, Rey E, et al. Effect of stiripentol on CBZ plasma concentration and metabolism in epileptic children. Eur J Clin Pharmacol 1996;50:497500.
  • 23
    Levy RH, Loiseau P, Guyot M, Acheampong A, Tor J, Retten-meier AW. Effect of stiripentol on valproate plasma concentration and metabolism. Epilepsia 1987;28: 605.
  • 24
    Kerr BM, Rettie AE, Eddy AC, et al. Inhibition of human liver microsomal epoxide hydrolase by valproate and valpromide: in vitro/in vivo correlation. Clin Pharmacol Ther 1989;46:8293.
  • 25
    Commission on Antiepileptic Drugs of the International League Against Epilepsy. Workshop on antiepileptic drug trials in children. Epilepsia 1991;32:2845.
  • 26
    Chiron C, Dulac O, Gram L. Vigabatrin withdrawal randomized study in children. Epilepsy Res 1996;25:20915.
  • 27
    Luna D, Dulac O, Pajot N, Beaumont D. Vigabatrin in the treatment of childhood epilepsies: a single-blind placebo controlled study. Epilepsia 1989;30:4307.
  • 28
    Dulac O, Chiron C, Luna D, et al. Vigabatrin in childhood epilepsy. J Child Neurol 1991;6: 2S307.
  • 29
    Dalla Bernardina B, Fontana E, Vigevano F, et al. Efficacy and tolerability of vigabatrin in children with refractory partial seizures: a single-blind dose-increasing study. Epilepsia 1995;36:68791.
  • 30
    Nabbout R, Chiron C, Mumford J, Dumas C, Dulac O. Vigabatrin in partial seizures in children. J Child Neurol 1997;12:1727.
  • 31
    Dulac O, Bulteau C, Pedersen S, Uldall P. The challenges of epilepsy in children. Epilepsia 1997;38: S14.
  • 32
    Elterman R, Glauser TA, Ritter FJ, et al. Topiramate YP study team: a double-blind trial of topiramate in partial seizures in children. Epilepsia 1997; 38(suppl.3):131.
  • 33
    Kerr BM, Martinez-Lage JM, Viteri C, Tor JA, Eddy AC, Levy RH. CBZ dose requirements during stiripentol. Epilepsia 1991;32:26774.
  • 34
    Doose H, Baier WK. Epilepsy with primarily generalised myoclonic-astatic seizures: a genetically determined disease. Eur J Pediatr 1987;146:5504.
  • 35
    Dulac O, Kaminska A. Use of lamotrigine in Lennox-Gastaut and related epilepsy syndromes. J Child Neurol 1997;12: S238.
  • 36
    Guerrini R, Dravet C, Genton P, Belmonte A, Kaminska A, Dulac O. Lamotrigine and seizure aggravation in severe myoclonic epilepsy. Epilepsia 1998;39: S0812.
  • 37
    Gerson WT, Fine DG, Spielberg SP, Sensenbrenner LL. Anticon-vulsant induced aplastic anemia: increase susceptibility to toxic drug metabolites in vitro. Blood 1983;61:88993.